Press Releases

AbbVie a global biopharmaceutical company announced that the EC approved IMBRUVICA® (ibrutinib) as a first-line treatment option for adult patients with chronic lymphocytic leukemia (CLL), expanding upon the initial EC approval in October 2014 for certain patients with CLL....

Label Now Includes New Data on Use of TEFLARO in Pediatric Patients 2 Months of Age to Less than 18 Years of Age with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP). ...

The European Commission (EC) granted marketing authorization in the European Union (EU) for FLIXABI®, an infliximab biosimilar referencing Remicade®i. FLIXABI was developed by Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen. FLIXABI is indicated...

AbbVie , Eisai Co Ltd. and its subsidiary EA  Pharma Co Ltd. announced the additional approval for a new dosing regimen of Humira® Pre-filled Syringe 40 mg/0.8 mL for Subcutaneous Injection (generic name: adalimumab , “Humira”). ...

Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of ZEPATIER™ (elbasvir and grazoprevir), an investigational, once-daily, fixed-dose combination tablet for the treatment...

GlaxoSmithKline (GSK), Fondazione Telethon (Telethon) and Ospedale San Raffaele (OSR) announced that the European Commission has approved Strimvelis, the first ex-vivo stem cell gene therapy to treat patients with a very rare disease called ADA-SCID (Severe Combined Immunodeficiency due...

AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of saxa/dapa (saxagliptin and dapagliflozin) tablets for the treatment of adults with type-2 diabetes....